Enanta Pharmaceuticals | ENTA - Ingresos Por Ventas





Ventas Cambio Fecha
AbbVie USD 16.99B 1.99B 2026-06
Amgen USD 10.1B 1.48B 2026-06
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 75.23M 1.49M 2026-06
AstraZeneca USD 15.38B 90M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Biogen USD 2.74B 490M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Halozyme Therapeutics USD 481M 104M 2026-06
Heron Therapeutics USD 40.59M 2.38M 2025-12
Incyte USD 1.67B 400M 2026-06
Insmed USD 425.49M 119.53M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
J&J USD 25.31B 1.21B 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
Ligand Pharmaceuticals USD 83.7M 31.98M 2026-06
Merck USD 16.6B 310M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06